Expanded Access Use of Adagrasib (MRTX849) for the Treatment of Patients With Advanced Solid Tumors With a KRAS G12C Mutation

Bristol-Myers Squibb11 个研究点分布在 1 个国家开始时间: 2021年12月17日最近更新: 2025年8月26日

适应症

试验速览

阶段: 不适用
状态: Approved For Marketing
发起方
试验地点: 11

研究概览入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Histologically or cytologically confirmed diagnosis of an advanced/metastatic solid tumor
•Confirmed presence of a KRASG12C mutation
•Ineligible for an ongoing clinical trial of MRTX849
•No available or not eligible for standard of care treatment
•Adequate organ function
•CNS Metastases (within set parameters) are allowed
•ECOG performance status of ≤ 2

排除标准

•History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of MRTX849 treatment or result in inability to swallow
•Prior therapy targeting a KRAS G12C mutation
•Other active cancer

研究者

发起方

Bristol-Myers Squibb

申办方类型

Industry

责任方

Sponsor

研究点 (11)

Loading locations...

相似试验

Approved For Marketing

不适用

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment OptionsAdvanced Cancers and FGFR Genetic Alterations

NCT03825484Janssen Scientific Affairs, LLC

Approved For Marketing

不适用

Margetuximab Expanded Access Program

NCT03133988TerSera Therapeutics LLC

No Longer Available

不适用

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)

NCT05086094Biohaven Pharmaceuticals, Inc.

Approved For Marketing

不适用

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung Cancer

NCT04599712Janssen Research & Development, LLC

Available

不适用

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular Lymphoma

NCT05776160Kite, A Gilead Company